Andres Valdivia

Andres Valdivia

Auto-generated profile, based on publicly available information

Andres Valdivia

Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
HHHao Huang
Hao Huang
GZGuangyuan Zhao
Guangyuan Zhao
HCHoracio Cardenas
Horacio Cardenas
AVAndres Felipe. Valdivia
Andres Felipe. Valdivia
YWYinu Wang
Yinu Wang
Daniela MateiDaniela Matei
Daniela Matei
Development of resistance to platinum (Pt) in ovarian cancer remains a major clinical challenge. Here we focused on identifying epitranscriptomic modifications linked to Pt resistance. Fat mass and obesity-associated protein (FTO) is a N6-methyladenosine (m6A) RNA demethylase that we recently described as a tumor suppressor in ovarian cancer. We hypothesized that FTO-induced removal of m6A marks regulates the cellular response of ovarian cancer cells to Pt and is linked to the development of resistance. To study the involvement of FTO in the cellular response to Pt, we used ovarian cancer cells in which FTO was knocked down via short hairpin RNA or overexpressed and Pt-resistant (Pt-R) models derived through repeated cycles of exposure to Pt. We found that FTO was significantly downregulated in Pt-R versus sensitive ovarian cancer cells. Forced expression of FTO, but not of mutant FTO, increased sensitivity to Pt in vitro and in vivo (P < 0.05). Increased numbers of γ-H2AX foci, measuring DNA double-strand breaks, and increased apoptosis were observed after exposure to Pt in FTO-overexpressing versus control cells. Through integrated RNA sequencing and MeRIP sequencing, we identified and validated the enzyme nicotinamide N-methyltransferase (NNMT), as a new FTO target linked to Pt response. NNMT was upregulated and demethylated in FTO-overexpressing cells. Treatment with an NNMT inhibitor or NNMT knockdown restored sensitivity to Pt in FTO-overexpressing cells. Our results support a new function for FTO-dependent m6A RNA modifications in regulating the response to Pt through NNMT, a newly identified RNA methylated gene target.

1 November 2022 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
YZYaqi Zhang
Yaqi Zhang
YWYinu Wang
Yinu Wang
AVAndres Valdivia
Andres Valdivia
HHHao Huang
Hao Huang
Daniela MateiDaniela Matei
Daniela Matei
Cancer stem cells (CSC) represent a population of cancer cells responsible for tumor initiation, chemoresistance, and metastasis. Here, we identified the H3K79 methyltransferase disruptor of telomeric silencing-1–like (DOT1L) as a critical regulator of self-renewal and tumor initiation in ovarian CSCs. DOT1 L was upregulated in ovarian CSCs versus non-CSCs. shRNA-mediated DOT1 L knockdown decreased the aldehyde dehydrogenase (ALDH)+ cell population, impaired the tumor initiation capacity (TIC) of ovarian CSCs, and blocked the expression of stemness-associated genes. Inhibition of DOT1L's methyltransferase activity by the small-molecule inhibitor (DOT1Li) EPZ-5676 also effectively targeted ovarian CSCs. Integrated RNA-sequencing analyses of ovarian cancer cells in which DOT1 L was knocked down versus control cells and of ovarian CSCs versus non-CSCs, identified Wnt signaling as a shared pathway deregulated in both CSCs and in DOT1L-deficient ovarian cancer cells. β-catenin, a key transcription factor regulated by Wnt, was downregulated in ovarian cancer cells in which DOT1 L was knocked down and upregulated in DOT1 L overexpressing ovarian cancer cells. Chromatin immunoprecipitation (ChIP) revealed enrichment of the H3K79Me3 mark at the β-catenin promoter, suggesting that its transcription is regulated by DOT1L. Our results suggest that DOT1 L is critical for the self-renewal and TIC of ovarian CSCs by regulating β-catenin signaling. Targeting DOT1 L in ovarian cancer could be a new strategy to eliminate CSCs. Implications: This study found that the histone methyltransferase DOT1 L regulates the self-renewal and tumor initiation capacity of ovarian CSCs and suggests DOT1 L as a new cancer target.

4 October 2025 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
AVAndres Valdivia
Andres Valdivia
JZJoshua L. Zhu
Joshua L. Zhu
VHVanessa Hernandez
Vanessa Hernandez
PVPurav P. Vagadia
Purav P. Vagadia
NMNatalia Masnica
Natalia Masnica
Daniela MateiDaniela Matei
Daniela Matei
Tissue transglutaminase (TG2), a multifunctional enzyme involved in protein crosslinking through transamidation, fibronectin-integrin interactions and GTP hydrolysis, is upregulated in cancer. Due to its diverse functions, TG2 has been a challenging therapeutic target. Here, we investigate the use of PROteolysis TArgeting Chimeras (PROTACs) to degrade TG2 and inhibit its tumor-promoting functions in ovarian cancer models. We describe a novel family of VHL based PROTACs using a ligand that binds to the TG2 fibronectin interacting domain and a thiol ether PEG linker. Three structurally related PROTACs-P374, P404, and P405-induced significant proteasome dependent TG2 degradation at 24 h (p < 0.05), with stable effects at 48 h. These compounds also potently inhibited cell adhesion and migration (p < 0.005), outside-in signaling, and blocked TG2 enzymatic activity (p < 0.001). An unbiased evaluation using reverse phase protein array of P374-treated cells revealed 136 differentially expressed proteins, including protein networks related to cell adhesion and involved in extracellular matrix (ECM) interactions. P374 and P405 reduced omental colonization in vivo and P374 inhibited intraperitoneal tumor dissemination and growth. Visium HD based spatial profiling of human ovarian tumors identified TG2 as a highly enriched protein at the tumors invasive edge and the interface with the ECM. Together, our findings put forward novel TG2-targeting PROTACs which effectively degrade TG2, impair its functions, and block in-vivo tumor dissemination. These results highlight the potential development of TG2 degraders towards therapeutic targeting in ovarian cancer.

27 November 2025
Verified
Other
Open access
YZYaqi Zhang
Yaqi Zhang
YWYinu Wang
Yinu Wang
AVAndres Valdivia
Andres Valdivia
HHHao Huang
Hao Huang
Daniela MateiDaniela Matei
Daniela Matei
S1. DOT1L is important for stemness in OC cells. S2. Inhibition of DOT1L activity reduces ALDH+ ovarian CSCs. S3. Inhibition of DOT1L activity inhibits Wnt pathway. Table S1. Cell culture conditions Table S2. Antibodies Table S3. shRNA sequences Table S4. qRT-PCR Primers Table S5. ChIP-PCR Primers Table S6. Effects of DOT1L knockdown on tumor initiation capacity Table S7. Estimated 1/stem cell frequency in shCtrl and shDOT1L OVCAR5 cells in serial dilution assay experiment. Table S8. Top 35 downregulated genes from the RNA-sequencing analysis of OVCAR5 cells transduced with shRNA targeting DOT1L versus control shRNA. Table S9. Top 35 upregulated genes from the RNA-sequencing analysis of OVCAR5 cells transduced with shRNA targeting DOT1L versus control shRNA.

27 November 2025
Verified
Other
Open access
HHHao Huang
Hao Huang
GZGuangyuan Zhao
Guangyuan Zhao
HCHoracio Cardenas
Horacio Cardenas
AVAndres Felipe Valdivia
Andres Felipe Valdivia
YWYinu Wang
Yinu Wang
Daniela MateiDaniela Matei
Daniela Matei
Supplementary Figures and Tables